Insulet Corporation (PODD)
Nasdaq · Healthcare · Medical Devices
$135.62+2.98%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $9.4B
- P/E (trailing)
- 25.4
- Forward P/E
- 17.6
- 52-week range
- $126.40 – $354.88
- 52-week change
- −57.99%
- EPS (trailing)
- $5.34
- Analyst rating
- 2.0 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $2.7B (+30.73%)
- Net income
- $247M
- Operating margin
- 17.5%
- Diluted EPS
- $3.48
- Free cash flow
- $378M
From the company’s annual report on SEC EDGAR.
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Headquarters: Acton, United States · 5,400 employees · insulet.com